Investigating a new treatment for cancer pain using Resolvin D1.
Treatment of cancer pain by lipid mediator Resolvin D1: role of Prostaglandin and Endocannabinoid signaling
This study is looking at a natural compound called Resolvin D1, which comes from omega-3 fatty acids, to see if it can help relieve severe pain from bone tumors in cancer patients without the risks of addiction that come with opioids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10894859 on NIH RePORTER |
What this research studies
This research focuses on finding effective alternatives to opioids for managing severe cancer pain, particularly in patients with bone tumors. It explores the use of Resolvin D1, a natural compound derived from omega-3 fatty acids, which has shown promise in reducing pain without the addictive side effects associated with opioids. The study utilizes a mouse model to understand how Resolvin D1 works in the body to alleviate pain by targeting specific pain pathways and mechanisms. By examining its effects on pain sensitivity and neuronal function, the research aims to provide insights into safer pain management options for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from severe pain due to primary or metastatic bone tumors.
Not a fit: Patients who do not have cancer-related pain or those with pain from non-cancerous conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, non-addictive treatment for cancer pain that significantly improves patient quality of life.
How similar studies have performed: While the use of Resolvin D1 is a novel approach, preliminary data suggest that similar strategies targeting pain pathways have shown promise in other studies.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Khasabov, Sergey G — University of Minnesota
- Study coordinator: Khasabov, Sergey G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.